

**Regd. Office :**

Zydus Tower,  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1<sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p><b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p><b>Kind Attn.:</b> Famroze Pochara Asst. Vice President</p>
<p><b>Date:</b> February 16, 2017</p>	
<p><b>Re.:</b> Announcement</p>	

Dear Sir / Madam,

We are pleased to announce that the USFDA inspected our Moraiya facility from February 6, 2017 to February 15, 2017.

At the end of the inspection, no observation (483) is issued.

**About Zydus Cadila**


Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **Cadila Healthcare Limited**



**Upen H. Shah**  
Company Secretary

